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Background: Peripheral artery disease (PAD), a manifestation of systemic atherosclerosis that produces
blockages in the arteries supplying the legs, affects approximately 5% of Americans. We have previously,
demonstrated that a myopathy characterized by myoﬁber oxidative damage and degeneration is central
to PAD pathophysiology.
Objectives: In this study, we hypothesized that increased oxidative damage in the myoﬁbers of the
gastrocnemius of PAD patients is myoﬁber-type selective and correlates with reduced myoﬁber size.
Methods: Needle biopsies were taken from the gastrocnemius of 53 PAD patients (28 with early PAD and
25 with advanced PAD) and 25 controls. Carbonyl groups (marker of oxidative damage), were quantiﬁed
in myoﬁbers of slide-mounted tissue, by quantitative ﬂuorescence microscopy. Myoﬁber cross-sectional
area was determined from sarcolemma labeled with wheat germ agglutinin. The tissues were also
labeled for myosin I and II, permitting quantiﬁcation of oxidative damage to and relative frequency of the
different myoﬁber Types (Type I, Type II and mixed Type I/II myoﬁbers). We compared PAD patients in
early (N¼28) vs. advanced (N¼25) disease stage for selective, myoﬁber oxidative damage and altered
morphometrics.
Results: The carbonyl content of gastrocnemius myoﬁbers was higher in PAD patients compared to
control subjects, for all three myoﬁber types (po0.05). In PAD patients carbonyl content was higher
(po0.05) in Type II and I/II ﬁbers compared to Type I ﬁbers. Furthermore, the relative frequency and
cross-sectional area of Type II ﬁbers were lower, while the relative frequencies and cross-sectional area of
Type I and Type I/II ﬁbers were higher, in PAD compared to control gastrocnemius (po0.05). Lastly, the
type II-selective oxidative damage increased and myoﬁber size decreased as the disease progressed from
the early to advanced stage.
Conclusions: Our data conﬁrm increased myoﬁber oxidative damage and reduced myoﬁber size in PAD
gastrocnemius and demonstrate that the damage is selective for type II myoﬁbers and is worse in the
most advanced stage of PAD.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).B.V. This is an open access article u
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),Introduction
Peripheral arterial disease (PAD), is characterized by the for-
mation of atherosclerotic plaques that limit blood ﬂow to the legs,
and affects approximately 5% of the general population, with the
prevalence increasing to 15–20% in persons over 70 years [1]. PAD
is commonly divided in four clinical stages [1]. In the early stage of
PAD, the patients experience no symptoms. This stage is deﬁned as
Stage I (asymptomatic PAD) according to the Fontaine classiﬁca-
tion system. By far, the most common clinical manifestation ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Myopathy in PAD limbs is easily demonstrated. Control skeletal muscle (A) and ischemic muscle from age- and sex-matched PAD patients with early (B) and late stage
(C) disease were stained with Masson trichrome and images were captured under bright-ﬁeld conditions with a 10 objective. Control muscle (A) exhibits polygonal
myoﬁbers of uniform shape and size and thin endomysium and perimysium. Myoﬁber shape and size are less uniform in early stage PAD muscle (B). The specimen includes
large, swollen ﬁbers, irregularly-shaped microﬁbers and thickened, collagenous endomysium and perimysium. Most myoﬁbers of late stage muscle (C) are irregular in shape
and size and include many large, rounded and swollen ﬁbers and many small, irregularly shaped ﬁbers. There is extensive replacement of myoﬁbers with ﬁbrous tissue. The
black bars represent a length of 100 mm.
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functional limitation identiﬁed as gait dysfunction and walking-
induced leg muscle pain relieved by rest. In its less common
advanced stages, symptomatic PAD becomes limb-threatening and
patients have foot pain at rest (i.e., Fontaine Stage III) or more
commonly non-healing ulcers and necrosis/gangrene (i.e., Fon-
taine Stage IV).
Previous studies, have documented a myopathy in the PAD
muscle that is characterized by defective mitochondrial bioener-
getics, oxidative stress and abnormal skeletal muscle histomor-
phology and function (Fig. 1) [2–10]. Our group has previously
shown the central importance of oxidative damage in the patho-
physiology of PAD myopathy demonstrating a signiﬁcant increase
in oxidative damage in PAD muscle and its myoﬁbers compared to
controls. At the myoﬁber level, we found that the levels of
oxidative damage in PAD increase as the hemodynamics of the
blood ﬂow to the leg worsen and as the disease advances from
Fontaine stage II to stage III and stage IV [10]. Furthermore, we
have shown that oxidative damage is not a homogeneously diffuse
process but varies from myoﬁber to myoﬁber in the affected
muscles and that the more atrophic myoﬁbers have higher levels
of oxidative damage [10]. Mechanistically, it is not known whether
oxidative damage in PAD limbs is selective for a speciﬁc subpo-
pulation of myoﬁbers and whether certain characteristics of
myoﬁbers may make them more sensitive or prone to oxidative
damage.
The myoﬁbers of human muscles belong to three classes
differentiated on the basis of myosin heavy chain phenotype and
differing on the basis of their speed of contraction and predomi-
nant type of energy metabolism [11]. Type I (slow twitch) ﬁbersTable 1
Baseline characteristics of PAD and control subjects.
Control subjects PAD patients
Combined
Number of subjects 25 53
Mean age (years) 62.772.1 64.771.0
Ankle brachial index 1.0870.02 0.4070.04
Gender % (male/female) 80/20 94.3/5.7
Smoking 28.00% 67.9%
Coronary artery disease 24.0% 45.3%
Obesity 44.0% 22.6%
Dyslipidemia 52.0% 64.2%
Type 1 diabetes mellitus 32.0% 49.1%
Family history of PAD 12.0% 15.1%
Hypertension 72.0% 77.4%
Note: Continuous variables are presented as mean7S.E.M.
n p Values are for differences between control subjects and PAD patients “combined”
test was used for continuous variables.are characterized by higher mitochondrial content and more
oxidative energy metabolism. Type II (fast twitch) ﬁbers have a
lower mitochondrial content and greater dependence on glycoly-
sis. Mixed (Type I/II) ﬁbers are intermediate in mitochondrial
content and energy metabolism and are transitioning between
Type I and Type II ﬁbers. Other groups have previously evaluated
the different types of myoﬁbers in the gastrocnemius of ischemic
limbs of PAD patients. Their ﬁndings have demonstrated a ten-
dency for selective loss of Type II ﬁbers relative to Type I ﬁbers and
a signiﬁcant decrease in the average cross sectional area of
individual Type II ﬁbers [3,9]. Considering the possibility that the
ﬁnding of selective loss of Type II ﬁbers is related to increased
oxidative damage in this type of ﬁbers we hypothesized that
increased oxidative damage in ischemic muscle of PAD patients is
myoﬁber type selective and correlates with reduced myoﬁber size.
We also hypothesized that oxidative stress and its myoﬁber type
selectivity, will increase with advancing disease stage from stage II
to stage IV.Materials and methods
Human subjects
The experimental protocol was approved by the Institutional
Review Board, of the VA, Nebraska-Western Iowa and University of
Nebraska Medical Centers, and all subjects gave informed consent.
We recruited 53 patients evaluated for symptomatic PAD (Table 1).
Twenty eight patients presented with claudication (PAD-II; Fon-
taine Stage II) and twenty ﬁve presented with tissue loss (PAD-IV;PAD-II PAD-IV p-Valuen
28 25 _
62.671.7 67.071.6 0.340
0.5370.04 0.2570.04 o0.001
92.9/7.1 96/4 0.102
67.90% 68.00% 0.001
39.30% 52.00% 0.085
17.90% 28.00% 0.066
71.40% 56.00% 0.331
32.10% 56.00% 0.222
21.40% 8.00% 0.714
75.00% 80.00% 0.778
; chi-square or Fisher’s exact tests were used for categorical variables; independent t
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established on the basis of medical history, physical examination,
signiﬁcantly decreased ankle-brachial index (ABI) and computer-
ized or standard arteriography. We recruited twenty ﬁve patients
with normal blood ﬂow to their lower limbs, undergoing lower
extremity operations for indications other than PAD (Table 1).
These patients had no history of PAD symptoms, and all had
normal lower extremity pulses at examination. All controls were
selected to have normal ABIs at rest and after stress and all led
sedentary lifestyles.
Muscle biopsy
Gastrocnemius samples were obtained from the anteromedial
aspect of the muscle belly, 10 cm distal to the tibial tuberosity. All
biopsies were obtained with a 6 mm Bergstrom needle. The
samples were placed immediately into cold methacarn. After
48 h in methacarn, the specimens were transferred to cold
ethanol:H2O (50:50 v/v) and subsequently embedded in parafﬁn.
Quantitative ﬂuorescence microscopy
Parafﬁn-embedded biopsies sectioned at 4 mm were labeled
with three ﬂuorescent reagents for identifying Type I and Type II
ﬁbers and for quantiﬁcation of ROS-induced oxidative damage in
myoﬁbers. Slide specimens of gastrocnemius biopsies were depar-
afﬁnized, rehydrated, and treated with 100 mM citrate buffer
(pH 6.0) at 90 °C for 15 min. For measurement of protein carbonyls
[10,12], endogenous biotin was blocked and then carbonyl groups
were biotinylated by treatment of slide specimens, ﬁrst with 5 mM
EZ-Link Hydrazide Biocytin (Thermo Scientiﬁc-Pierce Protein Re-
search Products, Rockford, IL; #28020) in 100 mM 2-morpholi-
noethane sulfonic acid buffer (pH 6.5) for 1 h and then with cold
15 mM cyanoborohydride in Dulbecco’s PBS for 1 h. For labeling of
Type I and Type II ﬁbers, specimens were blocked with 10% goat
serum and treated with a mixture of mouse monoclonal antibody
speciﬁc for Type I MHC (1 mg/mL; Sigma-Aldrich, St. Louis, MO)
and a rabbit polyclonal antibody speciﬁc for Type II MHC (1 mg/mL;
Abcam, Cambridge, MA). Control slides were treated with a
mixture of mouse (1 mg/mL; eBioscience, San Diego, CA) and rabbit
IgG (1 mg/mL; eBioscience, San Diego, CA). After overnight incuba-
tion for 12 h at 4 °C, the slides were labeled for 1 h, at room
temperature, with a mixture of Alexa Fluors 488 conjugated
streptavidin (10 mg/mL; Life Technologies-Molecular Probes, Grand
Island, NY), an Alexa Fluors 555 conjugated goat anti-mouse IgG
(10 mg/mL; Life Technologies-Molecular Probes) and an Alexa
Fluors 647 conjugated goat anti-rabbit IgG (10 mg/mL; Life Tech-
nologies-Molecular Probes). The conditions for all the ﬂuorescent
labels were adjusted to achieve maximal ﬂuorescence signals
required for quantitative analysis [13,14]. Subsequently, myoﬁber
sarcolemmas were labeled for 1 h with Alexa Fluors 350 con-
jugated Wheat Germ Agglutinin (10 mg/mL; Life Technologies-
Molecular Probes). The specimens were mounted in ProLong
Golds anti-fade medium with DAPI (Life Technologies-Molecular
Probes). Duplicate slides of each biopsy specimen were analyzed.
Isotype control slides exhibited no detectable ﬂuorescence
labeling.
Image acquisition and analysis
Gray-scale (12-bit) ﬂuorescence images (13441044) were
captured with a wideﬁeld, epiﬂuorescence microscope (Leica
DMRXA2; North Central Instruments, Plymouth, MN) (10 objec-
tive; 0.5128 mm/pixel), a B/W CCD camera (Orca ER C4742-95;
Hamamatsu Photonics, Bridgewater, NJ) and HCImage Hamamatsu
software (64-bit v.4.1; Hamamatsu Photonics, Bridgewater, NJ). Anacquisition matrix was programed into the HCImage software to
cover the whole muscle specimen area, acquiring a range of 60–
150 microscopic frames per specimen yielding images of
80,64062,640–201,600156,600 pixels. At each location,
images were collected in ﬂuorescence channels corresponding to
each ﬂuorophore; (1) excitation at 350 nm and emission at
460 nm (Alexa Fluor 350), (2) excitation 480 nm and emission
at 535 nm (Alexa Fluor 488), (3) excitation 555 nm and emission at
565 nm (Alexa Fluor 555) and (4) excitation 647 nm and emission
at 670 nm (Alexa Fluor 647). The frames corresponding to each
ﬂuorophore were montaged in one large image to represent the
given (whole) specimen. Image segmentation was done with a
custom made Matlab algorithm (R2012a, Mathworks Inc., Natic,
MA), using thresholding, edge detection, regionprops and a set of
heuristics [2]. Labeled sarcolemma acquired at 460 nm provided a
binary image that served as an outline for each myoﬁber was
imposed on the images of Type I ﬁbers acquired at 565 nm (Fig. 2)
and Type II ﬁbers acquired at 670 nm (Fig. 2) ﬁbers. Then, images
of Type I and II ﬁbers were extracted separately as well as those
labeled with both Type I/II identiﬁed as mixed ﬁbers (Fig. 2).
Subsequently, images of carbonyl groups acquired at 535 nm were
extracted for each myoﬁber Types I, II and I/II (Fig. 2). Measure-
ments of myoﬁber size, including cross-sectional area, equivalent
diameter and perimeter, and myoﬁber shape, including roundness
and solidity, were calculated for each myoﬁber classiﬁed as Types
I, II, I/II. The methods describing how these parameters were
measured have been described in detail [2]. Brieﬂy, we calculated
(1) myoﬁber cross-sectional area, as the number of pixels enclosed
within a segmented myoﬁber, (2) myoﬁber perimeter, as the
number of pixels on the boundary of the myoﬁber, (3) equivalent
diameter, as the diameter of a circle that has the same area as the
segmented myoﬁber region, (4) roundness, as the equivalent
diameter x π divided by the perimeter of the segmented region,
and (5) solidity, deﬁned as the myoﬁber cross-sectional area
divided by the area of a ﬁtted convex hull. A ﬁtted convex hull is
the smallest convex polygon that can encompass the myoﬁber.
Statistical analyzes
Baseline characteristics between PAD patients and control
subjects were compared using chi-square or Fischer’s exact tests
for categorical variables and independent t-tests for continuous
variables. A one-way analysis of covariance was used to identify
differences between PAD and control groups for all myoﬁber types
adjusting for the effects of smoking status, followed by post-hoc
analyzes with Bonferroni correction. A one-factor repeated mea-
sures design was used to identify differences among ﬁber types
within each group, followed by post-hoc analyzes with Bonferroni
correction. Partial bivariate correlations were used to correlate
oxidative damage with myoﬁber morphology parameters adjust-
ing for the effect of smoking status. All analyzes were performed
using SAS statistical software version 9.3 (SAS Institute Inc., Cary,
North Carolina).Results
Subject demographics
The baseline demographic and clinical characteristics are pre-
sented in Table 1. As expected, PAD patients had signiﬁcantly
lower ABI values than control subjects (PAD 0.4070.04 vs. con-
trols: 1.0870.02, po0.001). Smoking status was signiﬁcantly
higher in PAD patients compared to controls (χ2¼10.9, p¼0.001).
No other differences were found among the PAD patients and
control subjects.
Fig. 2. Each muscle specimen was labeled for identiﬁcation of nuclei (A, bright nodes along the sarcolemma), sarcolemma (A, white outlines), and Type I (C) and Type II (D)
myosin heavy chain and for quantiﬁcation of myoﬁber carbonyl content (B, gray). Sarcolemmal outlines of Type I (C, green outlines) and Type II (D, red outlines) ﬁbers were
superimposed on the carbonyl image (B), permitting quantiﬁcation of mean carbonyl content (gray) for each myoﬁber type. Morphometrics were determined from the
sarcolemmal images of each ﬁber type. The white bar represents a length of 100 microns.
Fig. 3. Representative images of gastrocnemius specimens are from a control subject (A and B) and a PAD patient (C and D) (10x). Each muscle specimen was labeled for
quantiﬁcation of carbonyl content (A and C, green) and for identiﬁcation of nuclei (blue nodes along the sarcolemma), sarcolemma (blue outlines) and Type I (yellow, B and
D), Type II (red, B and D) and Type I/II (orange, D) myosin heavy chains. PAD myoﬁbers exhibited higher carbonyl content as indicated by the brighter, green signal (compare
A and C), a larger proportion of Type I ﬁbers (yellow, compare B and D) and smaller cross-sectional area (compare B and D). Hybrid ﬁbers contained both Type I and Type II
myosin heavy chain (orange, D). The white bars represent a length of 100 mm.
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Table 2
Carbonyl content and morphometric parameters of PAD and control gastrocnemius
myoﬁbers.
Control PAD % Difference p-valuen
Type I 1137750 1424733 ↑ 25 o0.001
Type II 1175749 1578732 ↑ 34 o0.001
Type I/II 1251768 1601743 ↑ 28 o0.001
Combined 1216747 1519733 ↑ 25 o0.001
Cross-sectional area
Type I
57487316 41547214 ↓ 28 o0.001
Cross-sectional area
Type II
56927331 34087221 ↓ 40 o0.001
Cross-sectional area
Type I/II
55507381 35387236 ↓ 36 o0.001
Combined 56427246 37007176 ↓ 34 o0.001
Equivalent diameter
Type I
15375.4 13473.6 ↓ 12 0.009
Equivalent diameter
Type II
15076.1 11774.1 ↓ 22 o0.001
Equivalent diameter
Type I/II
15176.8 12174.0 ↓ 20 o0.001
Combined 15274.6 12473.3 ↓ 20 o0.001
Perimeter Type I 626722 549715 ↓ 12 0.009
Perimeter Type II 632724 500716 ↓ 21 o0.001
Perimeter Type I/II 616725 525715 ↓ 15 0.004
Combined 626721 524712 ↓ 16 o0.001
Solidity Type I 0.94170.003 0.93070.002 ↓ 1.2 0.009
Solidity Type II 0.93570.006 0.90270.004 ↓ 3.5 o0.001
Solidity Type I/II 0.89270.009 0.86370.006 ↓ 3.2 0.004
Combined 0.92370.002 0.89870.003 ↓ 2.7 o0.001
Roundness Type I 0.63070.008 0.63270.005 ↑ 0.3 0.793
Roundness Type II 0.63270.011 0.5977 .008 ↓ 5.5 0.015
Roundness Type I/II 0.55470.014 0.54970.009 ↓ 0.9 0.756
Combined 0.60970.007 0.59270.006 ↓ 2.8 0.094
n p-Values are adjusted for the effect of smoking status.
Table 3
Carbonyl content and morphometric parameters in PAD-II and PAD-IV patients.
PAD-II PAD-IV % Difference p-valuen
Type I 1329741 1496744 ↑ 12 0.009
Type II 1493745 1643748 ↑ 10 0.028
Type I/II 1483757 1701761 ↑ 15 0.012
Combined 1435734 1613753 ↑ 12 0.008
Cross-sectional area
Type I
47477262 34977277 ↓ 26 0.002
Cross-sectional area
Type II
42947208 25197252 ↓ 41 o0.001
Cross-sectional area
Type I/II
45237219 24537232 ↓ 45 o0.001
Combined 45217162 28237203 ↓ 38 o0.001
Equivalent diameter
Type I
145 74.2 12274.5 ↓ 15 o0.001
Equivalent diameter
Type II
13174.6 9974.9 ↓ 24 o0.001
Equivalent diameter
Type I/II
14074.1 9874.3 ↓ 30 o0.001
Combined 13973.1 10773.9 ↓ 23 o0.001
Perimeter Type I 586716 506717 ↓ 14 0.002
Perimeter Type II 546718 443719 ↓ 19 o0.001
Perimeter Type I/II 605715 437715 ↓ 28 o0.001
Combined 57979.8 462714 ↓ 20 o0.001
Solidity Type I 0.93870.003 0.92170.003 ↓ 1.8 o0.001
Solidity Type II 0.91870.005 0.88470.005 ↓ 3.7 o0.001
Solidity Type I/II 0.86170.007 0.86170.008 0 0.981
Combined 0.90570.003 0.88970.004 ↓ 1.8 0.003
Roundness Type I 0.64570.007 0.61970.007 ↓ 4.0 0.013
Roundness Type II 0.62470.009 0.56470.010 ↓ 9.6 o0.001
Roundness Type I/II 0.55270.011 0.54470.011 ↓ 1.4 0.609
Combined 0.60670.005 0.57570.008 ↓ 5.1 0.004
n p-Values are adjusted for the effect of smoking status.
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oxidative damage, reduced myoﬁber size and altered morphology
Myoﬁbers of PAD patients (n¼53) exhibited a 25% greater
burden of carbonyl groups (oxidative damage) (all myoﬁber types
combined) compared to myoﬁbers of control patients (n¼25;
Fig. 3). Furthermore, carbonyl content was signiﬁcantly greater
for each individual ﬁber Type in the PAD patients compared to
controls (Table 2). In addition, almost every parameter of size and
shape was signiﬁcantly different in the myoﬁbers (all myoﬁber
types combined) of PAD patients compared to controls. This was
also true for each individual Type of myoﬁber in PAD gastrocne-
mius compared to controls (Table 2).
Increased oxidative damage correlated inversely with the
observed abnormalities in the size and shape of PAD myoﬁbers,
suggesting that increased oxidative damage produced loss of
structural integrity of PAD myoﬁbers. Speciﬁcally, the carbonyl
content of PAD myoﬁbers (all myoﬁber types combined) was
negatively associated with myoﬁber cross-sectional area (r¼
0.401, po0.001), equivalent diameter (r¼0.346, p¼0.002),
perimeter (r¼0.314, p¼0.005) and solidity (r¼0.305,
p¼0.007).
Type II and Type I/II (mixed) myoﬁbers exhibited greater oxidative
damage compared to Type I myoﬁbers in PAD gastrocnemius
The variability of oxidative damage among myoﬁbers in in-
dividual PAD and control specimens suggested the possibility of
selective damage to the Type II ﬁbers, previously shown to bepreferentially affected in PAD muscle [3]. We found that oxidative
damage was higher in Type II and Type I/II ﬁbers compared to Type
I ﬁbers in PAD patients. Furthermore, Type II ﬁbers demonstrated
34% increase (highest increase among the different myoﬁber
types) of carbonyl content compared to control (Table 2). In PAD
gastrocnemius, Type II and Type I/II ﬁbers demonstrated greater
damage compared to Type I (Type I vs. Type II, po0.001; Type I vs.
Type I/II, po0.001). In the control gastrocnemius no differences
were observed among the ﬁber types.Type II and Type I/II (mixed) myoﬁbers exhibited a greater reduction
in size and alteration in shape compared to Type I myoﬁbers in PAD
gastrocnemius
Similar to the oxidative damage results, the parameters of
myoﬁber size including cross-sectional area, equivalent diameter
and perimeter and myoﬁber shape including solidity and round-
ness were signiﬁcantly reduced in the PAD gastrocnemius myoﬁ-
bers compared to controls for all three myoﬁber types (Table 2).
Furthermore, in comparison to Type I myoﬁbers, Type II ﬁbers
exhibited a greater decrease in cross-sectional area (po0.001),
equivalent diameter (po0.001), perimeter (po0.001), solidity
(p¼0.020) and roundness (p¼0.001) (Table 3). Type I/II compared
to Type I ﬁbers exhibited decreased cross-sectional area
(p¼0.002), equivalent diameter (po0.001), perimeter
(p¼0.007), and roundness (p¼0.019) (Table 3). No differences
were observed between Type II and Type I/II ﬁbers.
Fig. 4. Frequency of each ﬁber type in muscle from control subjects, PAD patients
presenting with claudication (Fontaine stage II, PAD-II) and PAD patients presenting
with critical limb ischemia (Fontaine stage IV, PAD-IV) is presented as percentage of
all myoﬁbers. The percentage of Type II ﬁbers decreased while the percentage of
Type I/II increased, as the disease progressed.
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and altered myoﬁber morphometrics as the disease progressed
To evaluate the hypothesis that oxidative damage and myoﬁber
size and shape are associated with the patient’s stage of disease,
we separated the PAD group (Table 1) into PAD Fontaine Stage II
(Stage II, n¼28 patients) and PAD Fontaine Stage IV (Stage IV,
n¼25 patients) and evaluated differences in myoﬁber oxidative
damage and morphometrics in the gastrocnemius of the two
groups (Table 3). Carbonyl content for all three ﬁber types was
signiﬁcantly increased in the PAD-IV patients compared to PAD-II
patients (Table 3). Similarly, myoﬁber cross-sectional area, equiva-
lent diameter, perimeter, solidity and roundness were signiﬁcantly
reduced in PAD-IV patients compared to PAD-II patients (Table 3).
Among the myoﬁbers of PAD-II patients, Type II ﬁbers exhibited
the most damage for all the parameters (p o 0.01) with the
exception of solidity and roundness compared to Type I ﬁbers. In
contrast, in PAD-IV myoﬁbers both Type II and Type I/II ﬁbers were
equally damaged compared to Type I ﬁbers.
Type II ﬁbers were preferentially lost, in PAD
Frequency analysis of Type I, Type II and Type I/II myoﬁbers
provided further support for our ﬁndings of selective oxidative
damage to Type II myoﬁbers with a shift in the ratio of Type II to
Type I myoﬁbers in PAD (Fig. 4). In the gastrocnemius of the control
group, the proportion of Type I, Type II and transitional Type I/II
ﬁbers was 48%, 51% and 1%, respectively. In the gastrocnemius of
PAD-II patients, the proportion of Type I, Type II and transitional Type
I/II ﬁbers was 56%, 42% and 2%, respectively. In PAD-IV patients the
proportion of Type I, Type II and transitional Type I/II ﬁbers was 56%,
38% and 6%, respectively. The data are consistent with a shift from
Type II myoﬁbers to Type I for both PAD groups (po0.01) and
indicate that with advancing disease there is a shift from Type II to
Type I, transitioning through Type I/II.Discussion
Our study of gastrocnemius muscle from patients with PAD
demonstrates increased oxidative damage in all ﬁber types in the
PAD patients compared to control subjects. Increased oxidative
damage was associated with reduced size (decrease in cross-
sectional area, equivalent diameter and perimeter) and abnormal
shape (less polygonal and more irregular) of myoﬁbers across allﬁber types. Reports of preferential loss of Type II ﬁbers in PAD
skeletal muscle [3,9,15], led us to hypothesize that this loss is
related to increased oxidative damage in Type II myoﬁbers. In
support of this hypothesis, our present study revealed greater
oxidative damage in Type II compared to Type I myoﬁbers in
association with smaller ﬁber size and more pronounced abnorm-
alities in ﬁber shape, changes that indicate signiﬁcant damage to
the myoﬁbrillar, cytoskeletal and membranous components of the
myoﬁber [16,17]. We also observed increased frequency, higher
levels of oxidative damage and markedly altered size and shape of
hybrid ﬁbers (Type I/II) in PAD compared to control gastrocnemius.
Hybrid ﬁbers represent transitions between Type II and Type I
ﬁbers and become more numerous whenever ﬁber type shifts
occur [18]. Therefore, the hybrid myoﬁbers in PAD muscle are
probably oxidatively damaged Type II myoﬁbers transitioning to
the Type I phenotype hence their higher carbonyl content, smaller
size and increased frequency, with disease progression. In general,
we found that for all myoﬁber types, oxidative damage, cross-
sectional area and shape abnormalities are directly related to
progression from claudication to tissue loss (critical limb ische-
mia). Taken together, our data demonstrate that in PAD, chronic
ischemia and ischemia-reperfusion operate to increase oxidative
damage that produces severe myopathic changes in the gastro-
cnemius muscle. The myopathy of PAD is characterized by pre-
ferential oxidative damage and degeneration of the fast twitch
(Type II) myoﬁbers and a fast (Type II) to slow (Type I) myoﬁber
type shift represented by a decrease of Type II ﬁbers and a
concomitant increase of the Type I and mixed Type I/II ﬁbers.
Muscle wasting is present in a variety of clinical conditions
including disuse, denervation, microgravity, heart failure, chronic
obstructive pulmonary disease, cachexia of cancer and sepsis and
sarcopenia of aging [18,19]. In most of these conditions reduced
myoﬁber size occurs preferentially in certain ﬁber types and/or is
accompanied by shifts in the ﬁber type proﬁle. Preferential
reduction in the size of Type I ﬁbers and a slow to fast myoﬁber
shift is usually seen in the leg muscles of patients after disuse,
denervation injury (nerve or spinal cord trauma), exposure to
microgravity (space travel), heart failure or chronic obstructive
pulmonary disease [18,19]. In contrast, a preferential reduction in
the size of Type II ﬁbers and a fast to slow shift is usually seen in
the leg muscles of patients suffering from cancer, dietary insufﬁ-
ciency, sepsis and sarcopenia of aging [18,19]. Our ﬁndings suggest
that the myopathy of PAD shares some similarities with the muscle
wasting seen in diseases of nutrient-deﬁciency like cancer, sepsis
and aging. This is potentially important for several reasons. First, it
points to possible analogies between the mechanisms operating to
produce the myopathy of PAD and those of cancer and aging [20–
22]. Such mechanisms may (among others explored below)
include a structural and dynamic malfunction of the vascular
system in these diseases [23,24]. Second, it suggests that although
decreased functional performance and activity is one of the
prominent manifestations of PAD, it is unlikely that a disuse type
of muscle wasting (usually seen with limb inactivity/immobiliza-
tion or nerve injury) is a dominant contributor to the myopathy of
PAD.
The mechanism of selective loss of Type II myoﬁbers in PAD has
not yet been established. Our results suggest that this loss is a
consequence of selective oxidative damage to the Type II ﬁbers
(Fig. 4). To date, remarkably few investigations have been con-
cerned with the biochemical basis for selective oxidative damage
to and reduced size of Type II ﬁbers in disease and aging. In a
recent study of rat skeletal muscle, Anderson and Neufer [25]
found a signiﬁcantly higher mitochondrial free radical leak,
expressed as the ratio of H2O2 production to O2 utilization, in
white (predominantly Type IIB ﬁbers) and red (predominantly
Type IIA ﬁbers) gastrocnemius, compared to soleus muscle
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were potentiated uniquely to generation of H2O2. In a related
study, Stefanyk et al. [26] identiﬁed a potential mechanism that
could explain our present ﬁndings of ﬁber type selective oxidative
damage and altered morphometrics. While studying fatty acid
composition of mitochondrial membranes from soleus, red gastro-
cnemius and plantaris (predominantly Type IIB ﬁbers) muscle of
the rat, these investigators found a signiﬁcantly higher mole
fraction of saturated fatty acids and a lower mole fraction of ω6
polyunsaturated fatty acids in the soleus, compared to red gastro-
cnemius and plantaris. The unsaturation index and, therefore, the
lipid peroxidation index were lower in the soleus. Similarly,
cardiolipin of the mitochondrial membranes of the soleus con-
tained more saturated fatty acids and less polyunsaturated fatty
acids than the mitochondrial membranes of red gastrocnemius
and plantaris, producing 20–30% lower unsaturation and lipid
peroxidation indices in the soleus. Taken together, these ﬁndings
are consistent with our present ﬁndings of increased sensitivity of
II ﬁbers to oxidative damage, leading to their preferential loss and
a shift towards Type I myoﬁbers in PAD.
A substantial body of work has explored the subject of muscle
wasting and its relation to different acute or chronic diseases and
aging and excellent reviews on the subject have been recently
published [18,27]. At the molecular level certain common mechan-
isms appear to be related to preferential reduction in the size and
frequency of Type II ﬁbers in the nutrient-related (cancer, dietary
insufﬁciency, sepsis and aging) type of muscle wasting. These
mechanisms involve abnormal activation of the proteolytic path-
ways including the proteasomal and lysosomal pathways [28]. The
best explored signaling networks involved in the process are
related to the Forkhead box O family, the transforming growth
factor beta family, and nuclear factor-kappaB [29–33]. Type II
myoﬁbers are more sensitive to these mechanisms and a signiﬁ-
cant factor contributing the resistance of Type I ﬁbers is the
activity of peroxisome proliferator-activated receptor gamma
coactivator 1-alpha, a well described transcriptional coactivator
required for mitochondrial biogenesis, protection from proteolysis
and maintenance of the slow twitch, oxidative ﬁber phenotype of
Type I myoﬁbers [34–37].
This is a descriptive study and therefore its principal limitation
is that it cannot establish cause and effect linkages between
arterial blockages, oxidative damage, myoﬁber type degeneration
and PAD clinical manifestations. Instead, the study demonstrated
that there is increased oxidative damage in association with
degeneration of myoﬁber size and shape in PAD gastrocnemius,
that the damage is selective for Type II myoﬁbers and is worse in
the most advanced stage of PAD. These ﬁndings are in agreement
with prior work from our and other laboratories demonstrating
that arterial blockages in the legs of PAD patients produce
ischemia-induced oxidative stress and progressive accumulation
of oxidative damage to all the tissues (including muscle, nerves,
skin, and subcutaneous tissues) of the affected limb
[4,7,9,10,38,39]. In the long-term, this accumulation of oxidative
damage in the ischemic tissues leads to gradual decline of the PAD
limb and may contribute to progression of the manifestations of
the disease from claudication to critical limb ischemia and
eventual limb loss. Our ﬁndings are also consistent with the type
of functional disability we see in PAD patients. Speciﬁcally, in PAD
muscles Type II ﬁbers that are high, energy consumers and are
designed for short explosive movements appear to be preferen-
tially lost while Type I ﬁbers that are energy conserving and are
optimized for prolonged low-intensity (fatigue resistant) activities
are less damaged and more represented in the PAD muscle [40].
This selectivity may in part explain the fact that, compared to
controls, PAD patients walk with reduced cadence, have decreased
gait variability and decreased performance of the foot plantarﬂexors [41–43]. In this study, we evaluated oxidative damage in
different myoﬁber types as a correlate of myoﬁber degeneration
and PAD disease progression. In the future, more detailed evalua-
tion of the proteolytic pathways and signaling networks respon-
sible for myoﬁber degeneration and their Type II selectivity can be
also evaluated in muscle samples obtained from PAD patients.
High quality human data are critical for improving our knowledge
of the mechanisms operating to produce PAD myopathy and for
the development of speciﬁc therapies with validated biomarkers
of relevance to underlying mechanisms. Several therapies includ-
ing exercise, nutritional therapy, medications that enhance mito-
chondrial function and antioxidant defenses, androgens, growth
hormone, ghrelin and its mimetics, myostatin inhibitors and anti-
inﬂammatory agents have been proposed for the management of
acquired myopathies [18,19] and may be promising approaches to
the management of PAD patients.
In summary, our work demonstrates that there is increased
myoﬁber oxidative damage and degeneration in PAD gastrocne-
mius, that this damage is selective for Type II myoﬁbers and is
worse in the most advanced stage of PAD. These ﬁndings are
consistent with myoﬁber oxidative damage as a signiﬁcant con-
tributor to the pathophysiology of PAD and provide insight into
possible mechanisms behind the preferential damage of Type II
myoﬁbers and the chronic and progressive nature of PAD. Accu-
mulating oxidative damage in the ischemic limb may cause the
patient to transition from claudication to critical limb ischemia
and eventually limb loss. In the future this type of work can help
identify the mechanisms responsible for the myopathy of PAD and
can lead to a better understanding of the pathogenesis of the
disease and to the design of individualized and targeted interven-
tions essential for much needed improvement of diagnosis, staging
and treatment of patients suffering from PAD.Conﬂict of Interest
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